Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience

Recent developments in immunotherapy of acute myeloid leukemia

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells

Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells.

A phase III, double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy